RECURSION PHARMACEUTICALS INC CLAS (RXRX)
Health Care · Biotechnology / AI-Driven Drug Discovery · NASDAQ
Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug discovery and development process.
What RECURSION PHARMACEUTICALS INC CLAS does
Recursion Pharmaceuticals is a clinical-stage TechBio company that leverages its proprietary "Recursion Operating System" (OS)—an integrated AI-native drug discovery and development platform—to identify and advance novel therapeutic candidates. The company combines large-scale, multimodal biological data generation with AI/ML tools to streamline drug discovery, optimize clinical development, and synthesize small molecules. Its business model includes both an internal pipeline of clinical and preclinical programs and strategic partnerships with large biopharmaceutical companies to apply its platform for milestone-based discovery and development.
Themes: AI-enabled drug discovery, TechBio / computational biology, Precision medicine, Clinical-stage drug development, Machine learning for therapeutics
Fundamentals
- Price$3.50 as of 2026-08-21 close
- Market cap$1.9B as of 2026-08-21
- 1-year return-26.8% 2025-08-21 close $4.78 → 2026-08-21 close $3.50
- P/En/a negative earnings
- Net margin-945.9% as of 2026-08-24
- Gross margin+3.5% as of 2026-08-24
- ROE-50.4% as of 2026-08-24
- Debt / equity0.02 as of 2026-08-24
- Revenue growth (YoY)-15.1% as of 2026-08-24
- Revenue CAGR (3y)+23.3% SEC XBRL
- Beta1.10 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How RXRX compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How RECURSION PHARMACEUTICALS INC CLAS looks technically
RECURSION PHARMACEUTICALS INC CLAS (RXRX) is trading 7.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 338 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 51.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 7.3% below its 200-day average, the long-term trend line — a long-term downtrend | -7.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.28 | $3.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.77 | $3.77 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 338 trading days ago — a "death cross", a bearish long-term signal | 338 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 12.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 58.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($2.92 to $3.63) — its "stochastic" reading is 82 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 81.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.18 | $7.18 |
|---|---|---|
| From the 52-week high | it is 51.3% below its 52-week high (its highest price of the past year) | -51.3% |
| Above the 52-week low | it is 26.4% above its 52-week low (its lowest price of the past year) | +26.4% |
| Below the 52-week high | it is 51.3% below its highest point of the past year | 51.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $42.81 (set on 2021-07-13) | $42.81 |
| Given back of the 52-week move | over the past year its closes ranged ($2.84 to $6.79), and it has recovered roughly a quarter of its fall from last year’s high — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.28 to $5.41. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 16.7% |
| From the all-time high | it is 91.8% below its all-time high | -91.8% |
| Nearest price level | it is trading 8.5% below a resistance level at $3.80 — a price it turned at three times since 2025-04-09, most recently on 2026-06-02. Since 2024-08-21 it has 3 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +8.5% |
| All-time low | its lowest closing price on record is $2.77 (set on 2026-05-19) | $2.77 |
| Above the all-time low | it is 26.4% above its all-time low | +26.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 76% of it) | 24th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1945 between its high and its low — about 5.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1945 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.90 and $3.51 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.90 – $3.20 – $3.51 |
| Typical daily range (% of price) | its price moves about 5.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.6% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges below its 200-day average price (7.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.28× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.5% |
|---|---|---|
| Open gap | it gapped 6.0% above the previous close 2 sessions ago and has not traded back through the level it left behind at 3.09 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.0% |
| Gap filled | a 2.9% gap down opened on 2026-08-20 has been "filled" today — price traded back through the level the gap left behind, and it took 1 session to close | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.3 percentage points (the stock gained 13.6% while the market gained 2.3%) | +11.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 9.4 percentage points (the stock gained 12.5% while the market gained 3.1%) | +9.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 8.7 percentage points (the stock gained 2.3% while the market gained 11.1%) | -8.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 47.3 percentage points (the stock lost 26.8% while the market gained 20.5%) | -47.3% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 2.8% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.58 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | -2.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $3.30 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +6.0% |
Price levels it has turned at before
RXRX last closed at $3.50 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 12 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.80 | Resistance | 8.5% above the last close | turned there three times · 2025-04-09 to 2026-06-02 |
| $2.96 | Support | 15.3% below the last close | turned there twice · 2026-02-18 to 2026-06-11 |
| $4.09 | Resistance | 17.0% above the last close | turned there five times · 2025-05-07 to 2026-07-06 |
| $2.85 | Support | 18.6% below the last close | turned there twice · 2026-07-20 to 2026-07-28 |
| $2.79 | Support | 20.4% below the last close | turned there twice · 2026-03-30 to 2026-05-19 |
| $4.75 | Resistance | 35.6% above the last close | turned there four times · 2025-05-13 to 2025-08-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · lagging the market · Left an unfilled gap (5%+ in the last week) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.43 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$7.22 range $4.00 – $10.00; median $7.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RXRX
- Consensus EPS estimate-$0.2288 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["AI/ML approaches remain unproven at scale in drug discovery; benefits and timelines for platform efficiency gains remain subject to ongoing validation and proof-of-concept","Company is clinical-stage and unprofitable with significant cash burn; ability to reduce cash burn and achieve milestones from partnerships is uncertain","Dependence on collaborators (Roche, Genentech, Sanofi, and others) continuing R&D activities and milestone payments; loss of key partnerships could materially impact funding and pipeline progress"]
What changed in the latest 10-Q
AI-assisted comparison of RXRX's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-06) references 2025 Annual Report on Form 10-K for year ended December 31, 2025, whereas older filing (2025-11-05) references 2024 Annual Report for year ended December 31, 2024
- Newer filing adds detailed section 'Wholly Owned Pipeline Updates' with subsections on REC-1245 (RBM39), REC-4881 (MEK1/2), and REC-4539 (LSD1 inhibitor) including clinical trial data, safety tables, and expected milestones
- Newer filing adds statement 'Advancing partnered discovery, with over $500 million in milestone and upfront payments achieved to date'
- Newer filing includes new subsection 'Favorable Safety and PK Data for REC-1245 (RBM39)' with detailed trial data from Phase 1/2 DAHLIA study and adverse event table
- Newer filing includes new subsection 'Continued Momentum for REC-4881 (MEK1/2)' with Phase 2 proof-of-concept data and FDA engagement information
- Newer filing includes new subsection 'First Patient Dosed in REC-4539 (LSD1 inhibitor)' describing initiation of ENLYGHT Phase 1 clinical study in April
- Newer filing adds specific upcoming milestones table with dates for REC-4881, REC-1245, REC-7735, REC-102, REC-617, REC-3565, and REC-4539
- Newer filing mentions Sanofi partnership progress in AI-enabled chemistry with programs progressing toward development candidate designation
- Removed:
- Older filing (2025-11-05) included detailed 'Summary of Business Highlights' section with 'Portfolio - Internal and Partnered Programs' and 'Internal Pipeline Updates' covering REC-617 (CDK7) with extensive clinical data from ELUCIDATE Phase 1/2 trial; this detailed section is not present in newer filing
- Older filing included detailed description of REC-617 dose escalation data, MTD establishment at 10 mg, safety profile with specific TRAE percentages, GI toxicity comparisons with samuraciclib, and anti-tumor activity; newer filing removes this detailed REC-617 focus
- Older filing included extensive explanation of Recursion OS differentiation factors and 'full-stack platform' capabilities; newer filing streamlines this to briefer platform description
- Reworded:
- Older filing describes Recursion as 'a leading clinical stage TechBio company decoding biology'; newer filing describes it as 'a clinical-stage TechBio company with a mission to decode biology to radically improve lives'
- Older filing describes mission as 'industrializing drug discovery using the Recursion Operating System'; newer filing emphasizes 'integrated drug discovery and development platform' with 'end-to-end, AI-native capabilities'
- Older filing describes OS as 'a vertical platform of diverse technologies that enables us to map and navigate trillions of biological, chemical and patient-centric relationships'; newer filing describes it as providing 'end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development'
- Older filing emphasizes 'Real World' data and 'World Model' computational approach; newer filing emphasizes 'multimodal biological data generation' and 'AI-native capabilities' without those specific terms
- Notes:
- The newer filing appears truncated at the end ('In AI-enabled biology, Recursion expects to continue jointly translating insights from its l'), making it unclear if additional content was removed or simply cut off in the source provided
- The two filings cover different reporting periods (Q1 2026 for newer, Q3 2025 for older) so some pipeline progression differences reflect natural time passage rather than strategic changes
Risk Factors
- Added:
- Added bullet point about 'our ability to sell or license assets and re-invest proceeds into funding our long-term strategy' (filed 2026-05-06)
- Added reference to 'the projected impact of our ClinTech platform on our business' within the wet-lab validation bullet (filed 2026-05-06)
- Removed:
- Removed bullet point 'our ability to raise substantial additional funding' (was in filed 2025-11-05)
- Removed bullet point 'the impact of current and future laws and regulations, and our ability to comply with all regulations that we are, or may become, subject to' (was in filed 2025-11-05)
- Removed bullet point 'the need to hire additional personnel and our ability t[o]...' which appears truncated in older filing (was in filed 2025-11-05)
- Reworded:
- Changed 'our continued ability to achieve milestones' to 'our continued ability to achieve milestones and receive associated milestone payments and royalties from current and future collaborations' (filed 2026-05-06)
- Changed 'our ability to use our combined assets from our recent business combination' to 'our ability to use our combined assets from our business combination' - removed word 'recent' (filed 2026-05-06)
- Changed 'the timing and likelihood of our ability to shift our wet-lab from a source of data generation to a model for validating data from AI-generated results' to add 'and the projected impact of our ClinTech platform on our business' (filed 2026-05-06)
- Changed 'our ability to sell or license assets and re-invest proceeds into funding our long-term strategy' appears as new addition rather than rewording (filed 2026-05-06)
- Removed 'our ability to reduce our cash burn' statement that was present in newer filing (filed 2026-05-06)
- Notes:
- Both filings appear truncated at the end; full text comparison is incomplete
- Page numbering differs between filings (Item 1A on page 29 vs page 37, Item 2 on page 29 vs page 37, Item 6 on page 29 vs page 39)
- The newer filing text ends mid-sentence ('the period over which we estimate our existing cash and cash equivalents will be suf'), preventing complete assessment of all content
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($97500) — 1 selling insider
- Last 90 days0 buys · 7 sells ($623788) — 4 selling insiders
- Last 180 days0 buys · 11 sells ($1M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RXRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding RXRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 117,466,331
- Reported value $360,621,636
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RXRX had 180,771,459 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RXRX had 33.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.31 days to cover at the same settlement.
- Reported short interest (shares) 180,771,459
- Short interest (% of shares outstanding) 33.8%
- Prior settlement (shares) 180,760,541
- Reported change 0.01%
- Days to cover (reported) 9.31
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Exscientia
- Insilico Medicine
- Atomwise
- BenevolentAI
- Schrodinger (SDGR)
- Roche
- Genentech
- Sanofi
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RXRX vs…
RECURSION PHARMACEUTICALS INC CLAS is found in…
RXRX ranks in…
Frequently asked questions
What does RECURSION PHARMACEUTICALS INC CLAS (RXRX) do?
Recursion Pharmaceuticals is a clinical-stage TechBio company that leverages its proprietary "Recursion Operating System" (OS)—an integrated AI-native drug discovery and development platform—to identify and advance novel therapeutic candidates. The company combines large-scale, multimodal biological data generation with AI/ML tools to streamline drug discovery, optimize clinical development, and synthesize small molecules.
What sector is RECURSION PHARMACEUTICALS INC CLAS (RXRX) in?
RECURSION PHARMACEUTICALS INC CLAS (RXRX) is classified in the Health Care sector. Its industry is Biotechnology / AI-Driven Drug Discovery. It trades on NASDAQ.
Who are RECURSION PHARMACEUTICALS INC CLAS's (RXRX) competitors?
Notable peers of RECURSION PHARMACEUTICALS INC CLAS (RXRX) include Exscientia, Insilico Medicine, Atomwise, BenevolentAI and Schrodinger. This peer set is informational only — not financial advice.
Is RECURSION PHARMACEUTICALS INC CLAS (RXRX) overbought or oversold right now?
RECURSION PHARMACEUTICALS INC CLAS (RXRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RXRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.